COR-1004 vs Inclisiran
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
COR-1004
Developed by Corsera Health
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: February 2027 · NCT07229118 (registry estimate)
No aligned efficacy figure on record for this race.
Inclisiran · Leqvio
Marketed by Novartis and partners
NCT03397121 · Phase 3 · completed
The trial randomly assigned 482 participants to double-blind inclisiran or placebo, with 242 receiving inclisiran and 240 receiving placebo. Both primary LDL-C comparisons were statistically significant in favor of inclisiran, but LDL-C is a surrogate laboratory endpoint rather than a hard clinical outcome, supporting a moderate evidence grade.
Next expected readout: November 2026 · NCT06501443 (registry estimate)
Reported efficacy
Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -27.14% (95% CI -32.04 to -22.24) vs Part 1 - Placebo 1.4% (95% CI -3.97 to 6.78) (met)
Result source: NCT04652726
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | COR-1004 | Inclisiran |
|---|---|---|
| LDL-C, % change | —Not reported | -49.3% vs 4.2%−53.5 vs placeboNCT0340080076 other results
|
| Non-HDL-C, % change | —Not reported | -41.2% vs 2.1%−43.3 vs placeboNCT0340080038 other results
|
| ApoB, % change | —Not reported | -38.1% vs 0.8%−38.9 vs placeboNCT0340080038 other results
|
| Lp(a), % change | —Not reported | -9.3% vs 3.6%−12.9 vs placeboNCT0465272634 other results
|
| 3-point MACE (% with event) | —Not reported | —Not posted · NCT05004675 |
LDL-C, % change
- COR-1004
- —Not reported
- Inclisiran
- -49.3% vs 4.2%−53.5 vs placeboNCT03400800
76 other results
- -56.3% vs 1.3% NCT03399370
- -45.8% vs 3.4% NCT03400800
- -51.3% vs 2.5% NCT03399370
- -41.1% vs 8.4% NCT03397121
- -27.1% vs 1.4% NCT04652726
- -45.9% vs 1.6% NCT05888103
- -38.1% vs 6.2% NCT03397121
- 0.7% vs 2.4% NCT03851705
- -21.6% vs 11.7% NCT04659863
- -45.6% vs 1.4% NCT04873934
- -60% vs -7% NCT04929249
- -26.1% vs 1.5% NCT04652726
- -26.0% vs 3.3% NCT04652726
- -27.8% vs 1.5% NCT04652726
- -19% vs 2.1% NCT04652726
- -7.2% vs -1.5% NCT03851705
- -32.5% vs 6.4% NCT04652726
- 1.8% vs -2.9% NCT03851705
- -23.9% vs -0.1% NCT04652726
- -8.7% vs 3.3% NCT03851705
- -19.3% vs 5.4% NCT04659863
- -21.6% vs 11.7% NCT04659863
- -17.3% vs 10.2% NCT04659863
- -24.1% vs 17% NCT04659863
- -26.1% vs 6.8% NCT04659863
- -44.3% vs 2.4% NCT04873934
- -57.2% vs -2.8% NCT04929249
- -56.3% vs 9% NCT04666298
- -38.4% vs 2.1% NCT02597127
- -52.6% vs 2.1% NCT02597127
- -41.9% vs 2.1% NCT02597127
- -51.9% vs 9% NCT04666298
- -27.9% vs 2.1% NCT02597127
- -44.9% vs 2.1% NCT02597127
- -47.6% vs 9% NCT04666298
- -35.5% vs 2.1% NCT02597127
- -59.5% vs -24.3% NCT05192941
- -35.4% vs 1.4% NCT02597127
- -50.5% vs 1.4% NCT02597127
- -66.2% vs 4.3% NCT04666298
- -67.2% vs 2.3% NCT04666298
- -43.3% vs -0.9% NCT02597127
- -54.7% vs -0.9% NCT02597127
- -65.7% vs 1.2% NCT04666298
- -61.5% vs 2.7% NCT04666298
- -62.4% vs 0.2% NCT04666298
- -50.9% vs -4.3% NCT02597127
- -51.0% vs -4.3% NCT02597127
- -62.8% vs 1.3% NCT04666298
- -47.6% vs 1.7% NCT04666298
- -39.2% vs 1.4% NCT02597127
- -46.4% vs -0.9% NCT02597127
- -49.6% vs -4.3% NCT02597127
- -29.0% vs 1.4% NCT02597127
- -42.6% vs 1.4% NCT02597127
- -60.5% vs 4.3% NCT04666298
- -62.0% vs 2.3% NCT04666298
- -36.9% vs -0.9% NCT02597127
- -49.5% vs -0.9% NCT02597127
- -60.3% vs 1.2% NCT04666298
- -53.9% vs 2.7% NCT04666298
- -55.6% vs 0.2% NCT04666298
- -44.3% vs -4.3% NCT02597127
- -44.3% vs -4.3% NCT02597127
- -55.5% vs 1.3% NCT04666298
- -42.1% vs 1.7% NCT04666298
- -31.7% vs 1.4% NCT02597127
- -55.5% vs 4.3% NCT04666298
- -54.9% vs 2.3% NCT04666298
- -41.4% vs -0.9% NCT02597127
- -53% vs 1.2% NCT04666298
- -46.4% vs 2.7% NCT04666298
- -50.1% vs 0.2% NCT04666298
- -35.7% vs -4.3% NCT02597127
- -52.2% vs 1.3% NCT04666298
- -37.1% vs 1.7% NCT04666298
Non-HDL-C, % change
- COR-1004
- —Not reported
- Inclisiran
- -41.2% vs 2.1%−43.3 vs placeboNCT03400800
38 other results
- -47.4% vs -0.1% NCT03399370
- -34.9% vs 7.4% NCT03397121
- -24% vs 1.2% NCT04652726
- -25.0% vs 1.8% NCT04652726
- -25.7% vs 1.8% NCT04652726
- -6.2% vs -1.1% NCT03851705
- -29% vs 5.1% NCT04652726
- -40.7% vs -0.1% NCT05888103
- 1.3% vs -1.7% NCT03851705
- 0.4% vs 2.5% NCT03851705
- -7.2% vs 2.9% NCT03851705
- -20.1% vs 7.1% NCT04659863
- -23.3% vs 9.4% NCT04659863
- -24% vs 19% NCT04659863
- -54.0% vs 1.3% NCT04666298
- -56.8% vs 2.0% NCT04666298
- -58.7% vs 0.8% NCT04666298
- -57.7% vs 2.0% NCT04666298
- -53.2% vs 1.8% NCT04666298
- -54.1% vs 0.6% NCT04666298
- -54.2% vs 1.0% NCT04666298
- -41.2% vs 1.1% NCT04666298
- -50.1% vs 1.3% NCT04666298
- -52.9% vs 2.0% NCT04666298
- -53.5% vs 0.8% NCT04666298
- -52.0% vs 2.0% NCT04666298
- -47.2% vs 1.8% NCT04666298
- -48.2% vs 0.6% NCT04666298
- -48.0% vs 1.0% NCT04666298
- -35.7% vs 1.1% NCT04666298
- -44.8% vs 1.3% NCT04666298
- -47.9% vs 2.0% NCT04666298
- -48.2% vs 0.8% NCT04666298
- -46.1% vs 2.0% NCT04666298
- -39.8% vs 1.8% NCT04666298
- -43.4% vs 0.6% NCT04666298
- -44.7% vs 1.0% NCT04666298
- -31.4% vs 1.1% NCT04666298
ApoB, % change
- COR-1004
- —Not reported
- Inclisiran
- -38.1% vs 0.8%−38.9 vs placeboNCT03400800
38 other results
- -44.8% vs -1.7% NCT03399370
- -33.1% vs 2.9% NCT03397121
- -19.3% vs 1.7% NCT04652726
- -21.5% vs 4.2% NCT04652726
- -21.9% vs 3.9% NCT04652726
- -5.8% vs 4.5% NCT03851705
- -25.1% vs 2.2% NCT04652726
- -36.6% vs 0.2% NCT05888103
- -0.7% vs 2.8% NCT03851705
- -0.8% vs 3.5% NCT03851705
- -6.4% vs 6.3% NCT03851705
- -14.8% vs 10.6% NCT04659863
- -18.5% vs 4.5% NCT04659863
- -20.3% vs 10% NCT04659863
- -46.8% vs 3.8% NCT04666298
- -50.4% vs 3.9% NCT04666298
- -51.9% vs 2.0% NCT04666298
- -51.9% vs 3.0% NCT04666298
- -46.8% vs 2.8% NCT04666298
- -48.5% vs 1.4% NCT04666298
- -48.8% vs 2.2% NCT04666298
- -37.1% vs 1.1% NCT04666298
- -44.5% vs 3.8% NCT04666298
- -46.7% vs 3.9% NCT04666298
- -48.2% vs 2.0% NCT04666298
- -47.0% vs 3.0% NCT04666298
- -42.0% vs 2.8% NCT04666298
- -44.5% vs 1.4% NCT04666298
- -44.0% vs 2.2% NCT04666298
- -32.5% vs 1.1% NCT04666298
- -38.6% vs 3.8% NCT04666298
- -42.8% vs 3.9% NCT04666298
- -43.4% vs 2.0% NCT04666298
- -40.9% vs 3.0% NCT04666298
- -35.8% vs 2.8% NCT04666298
- -39.9% vs 1.4% NCT04666298
- -39.7% vs 2.2% NCT04666298
- -28.2% vs 1.1% NCT04666298
Lp(a), % change
- COR-1004
- —Not reported
- Inclisiran
- -9.3% vs 3.6%−12.9 vs placeboNCT04652726
34 other results
- -5.0% vs 1.1% NCT04652726
- -7.2% vs 1.1% NCT04652726
- -4.8% vs 4.9% NCT03851705
- -13.4% vs 5.4% NCT04652726
- -23.8% vs 6.4% NCT05888103
- -3.8% vs 15.2% NCT03851705
- -4.6% vs 4.3% NCT03851705
- -1.7% vs -12.1% NCT04659863
- -0.3% vs -16.5% NCT04659863
- -0.7% vs -4.4% NCT04659863
- -35.4% vs 5.5% NCT04666298
- -38.1% vs 4.0% NCT04666298
- -37.2% vs 0.2% NCT04666298
- -37.9% vs -2.4% NCT04666298
- -34.3% vs 4.3% NCT04666298
- -36.2% vs -4.3% NCT04666298
- -31.3% vs 0.9% NCT04666298
- -22.8% vs 3.3% NCT04666298
- -25.5% vs 5.5% NCT04666298
- -21.6% vs 4.0% NCT04666298
- -30.3% vs 0.2% NCT04666298
- -26.0% vs -2.4% NCT04666298
- -24.9% vs 4.3% NCT04666298
- -26.1% vs -4.3% NCT04666298
- -22.8% vs 0.9% NCT04666298
- -16.6% vs 3.3% NCT04666298
- -30.1% vs 5.5% NCT04666298
- -32.2% vs 4.0% NCT04666298
- -31.5% vs 0.2% NCT04666298
- -32.0% vs -2.4% NCT04666298
- -27.1% vs 4.3% NCT04666298
- -30.9% vs -4.3% NCT04666298
- -28.1% vs 0.9% NCT04666298
- -21.8% vs 3.3% NCT04666298
3-point MACE (% with event)
- COR-1004
- —Not reported
- Inclisiran
- —Not posted · NCT05004675
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
COR-1004: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. COR-1004: 0 of 4 rows · Inclisiran: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Inclisiran |
|---|---|
| Dropout rate | 2.9%a NCT03397121 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 46 more results—Part 1 - Inclisiran NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 2.2%Part 1- Inclisiran NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 —Part 1 - Inclisiran NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 0%Part 1- Inclisiran NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 —Part 2 - Inclisiran (Total) NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 4.7% NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 7.7% NCT03399370 · Phase 3 2% NCT05192941 · Phase 4 · registry result, not featured evidence 2.9%Inclisiran - Inclisiran NCT05888103 · Phase 3 · registry result, not featured evidence —Inclisiran - Inclisiran: Core Part NCT05888103 · Phase 3 · registry result, not featured evidence —Inclisiran - Inclisiran: Extension NCT05888103 · Phase 3 · registry result, not featured evidence —Inclisiran + Usual Care NCT04873934 · Phase 3 · registry result, not featured evidence · combination 9%Inclisiran With Usual Care NCT04873934 · Phase 3 · registry result, not featured evidence · combination 5.7% NCT05763875 · Phase 3 · registry result, not featured evidence 5.8% NCT04929249 · Phase 3 · registry result, not featured evidence 100%ORION-3 Rollover NCT03814187 · Phase 3 · registry result, not featured evidence 17.6%Phase III Inclisiran-Inclisiran NCT03814187 · Phase 3 · registry result, not featured evidence 18.8%Phase III Placebo-Inclisiran NCT03814187 · Phase 3 · registry result, not featured evidence 16.8%Inclisiran NCT04807400 · Phase 3 · registry result, not featured evidence 15.2%Inclisiran + BS NCT04807400 · Phase 3 · registry result, not featured evidence · combination 8.1%Part 1 - Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence —Part 1: Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence —Part 2 - Inclisiran-Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence —Part 2: Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence 4%300 mg NCT04666298 · Phase 2 · registry result, not featured evidence —300 mg NCT04666298 · Phase 2 · registry result, not featured evidence 1%200 mg NCT04666298 · Phase 2 · registry result, not featured evidence —200 mg NCT04666298 · Phase 2 · registry result, not featured evidence 0%100 mg NCT04666298 · Phase 2 · registry result, not featured evidence —100 mg NCT04666298 · Phase 2 · registry result, not featured evidence —Inclisiran Only Arm NCT03060577 · Phase 2 · registry result, not featured evidence 19.7%Inclisiran-only NCT03060577 · Phase 2 · registry result, not featured evidence —Switching Arm After Day 360 Visit NCT03060577 · Phase 2 · registry result, not featured evidence 55.6% NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy —300 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence 6.6%300 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence —300 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence 4.8%300 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —500 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence 12.1%500 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —200 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence 6.3%200 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence —200 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence 1.7%200 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —100 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence 8.1%100 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT03397121 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 46 more results—Part 1 - Inclisiran NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 —Part 1- Inclisiran NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 —Part 1 - Inclisiran NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 —Part 1- Inclisiran NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 —Part 2 - Inclisiran (Total) NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 — NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 — NCT03399370 · Phase 3 0.3% NCT05192941 · Phase 4 · registry result, not featured evidence —Inclisiran - Inclisiran NCT05888103 · Phase 3 · registry result, not featured evidence —Inclisiran - Inclisiran: Core Part NCT05888103 · Phase 3 · registry result, not featured evidence —Inclisiran - Inclisiran: Extension NCT05888103 · Phase 3 · registry result, not featured evidence —Inclisiran + Usual Care NCT04873934 · Phase 3 · registry result, not featured evidence · combination 0%Inclisiran With Usual Care NCT04873934 · Phase 3 · registry result, not featured evidence · combination 0.6% NCT05763875 · Phase 3 · registry result, not featured evidence 0.9% NCT04929249 · Phase 3 · registry result, not featured evidence 0%ORION-3 Rollover NCT03814187 · Phase 3 · registry result, not featured evidence 1.5%Phase III Inclisiran-Inclisiran NCT03814187 · Phase 3 · registry result, not featured evidence 1.6%Phase III Placebo-Inclisiran NCT03814187 · Phase 3 · registry result, not featured evidence 0.7%Inclisiran NCT04807400 · Phase 3 · registry result, not featured evidence 1%Inclisiran + BS NCT04807400 · Phase 3 · registry result, not featured evidence · combination —Part 1 - Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence —Part 1: Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence —Part 2 - Inclisiran-Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence —Part 2: Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence —300 mg NCT04666298 · Phase 2 · registry result, not featured evidence —300 mg NCT04666298 · Phase 2 · registry result, not featured evidence —200 mg NCT04666298 · Phase 2 · registry result, not featured evidence —200 mg NCT04666298 · Phase 2 · registry result, not featured evidence —100 mg NCT04666298 · Phase 2 · registry result, not featured evidence —100 mg NCT04666298 · Phase 2 · registry result, not featured evidence —Inclisiran Only Arm NCT03060577 · Phase 2 · registry result, not featured evidence 3.1%Inclisiran-only NCT03060577 · Phase 2 · registry result, not featured evidence —Switching Arm After Day 360 Visit NCT03060577 · Phase 2 · registry result, not featured evidence — NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy —300 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence —300 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence —300 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —300 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —500 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —500 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —200 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence —200 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence —200 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —200 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —100 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence —100 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 7.5%a NCT03397121 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 46 more results3.2%Part 1 - Inclisiran NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 —Part 1- Inclisiran NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 0%Part 1 - Inclisiran NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 —Part 1- Inclisiran NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 0%Part 2 - Inclisiran (Total) NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 22.3% NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 22.4% NCT03399370 · Phase 3 16.4% NCT05192941 · Phase 4 · registry result, not featured evidence —Inclisiran - Inclisiran NCT05888103 · Phase 3 · registry result, not featured evidence 4.9%Inclisiran - Inclisiran: Core Part NCT05888103 · Phase 3 · registry result, not featured evidence 1%Inclisiran - Inclisiran: Extension NCT05888103 · Phase 3 · registry result, not featured evidence 15.8%Inclisiran + Usual Care NCT04873934 · Phase 3 · registry result, not featured evidence · combination —Inclisiran With Usual Care NCT04873934 · Phase 3 · registry result, not featured evidence · combination 0.6% NCT05763875 · Phase 3 · registry result, not featured evidence 11.5% NCT04929249 · Phase 3 · registry result, not featured evidence 15.1%ORION-3 Rollover NCT03814187 · Phase 3 · registry result, not featured evidence 30.7%Phase III Inclisiran-Inclisiran NCT03814187 · Phase 3 · registry result, not featured evidence 32.6%Phase III Placebo-Inclisiran NCT03814187 · Phase 3 · registry result, not featured evidence 8.8%Inclisiran NCT04807400 · Phase 3 · registry result, not featured evidence 12.8%Inclisiran + BS NCT04807400 · Phase 3 · registry result, not featured evidence · combination —Part 1 - Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence 5.4%Part 1: Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence —Part 2 - Inclisiran-Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence 20.8%Part 2: Inclisiran NCT03851705 · Phase 3 · registry result, not featured evidence —300 mg NCT04666298 · Phase 2 · registry result, not featured evidence 7.1%300 mg NCT04666298 · Phase 2 · registry result, not featured evidence —200 mg NCT04666298 · Phase 2 · registry result, not featured evidence 6.9%200 mg NCT04666298 · Phase 2 · registry result, not featured evidence —100 mg NCT04666298 · Phase 2 · registry result, not featured evidence 3.6%100 mg NCT04666298 · Phase 2 · registry result, not featured evidence 36.6%Inclisiran Only Arm NCT03060577 · Phase 2 · registry result, not featured evidence —Inclisiran-only NCT03060577 · Phase 2 · registry result, not featured evidence 34.5%Switching Arm After Day 360 Visit NCT03060577 · Phase 2 · registry result, not featured evidence 25% NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy 14.8%300 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence —300 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence 18%300 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —300 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence 12.3%500 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —500 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence 12.9%200 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence —200 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence 18.3%200 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence —200 mg single dose NCT02597127 · Phase 2 · registry result, not featured evidence 21.3%100 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence —100 mg double dose NCT02597127 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a nasopharyngitis 11.6% (placebo 8.3%) injection site reaction 9.1% (placebo 0%) back pain 7.1% (placebo 4.2%) NCT03397121 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 30 more resultscovid-19 18.3% (placebo 25%) nasopharyngitis 14% (placebo 18.8%) headache 12.9% (placebo 6.3%) NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 covid-19 44.4% (placebo 25%) abdominal pain upper 22.2% (placebo 0%) injection site reaction 22.2% (placebo 0%) NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 headache 15.4% (placebo 0%) influenza 15.4% (placebo 0%) abdominal pain upper 7.7% (placebo 0%) NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3 nasopharyngitis 11.2% (placebo 11.2%) diabetes mellitus 10.9% (placebo 11.7%) hypertension 6.5% (placebo 6.7%) NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 diabetes mellitus 15.4% (placebo 13.9%) bronchitis 5.9% (placebo 3.9%) hypertension 5.4% (placebo 5.4%) NCT03399370 · Phase 3 nasopharyngitis 8.2% (placebo 9.1%) covid-19 6.1% (placebo 6.3%) diabetes mellitus inadequate control 6.1% (placebo 5.6%) NCT05192941 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 24.3% (placebo 16.3%) blood glucose increased 9.7% (placebo 6.7%) blood creatine phosphokinase increased 6.8% (placebo 5.8%) NCT05888103 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 14% (placebo 16.3%) blood creatine phosphokinase increased 6% (placebo 5.8%) alanine aminotransferase increased 5% (placebo 2.9%) NCT05888103 · Phase 3 · registry result, not featured evidence covid-19 4.9% injection site pain 4.9% arthralgia 3.9% NCT04873934 · Phase 3 · registry result, not featured evidence · combination headache 3.4% (placebo 0%) nasopharyngitis 3.4% (placebo 3.4%) urinary tract infection 1.7% (placebo 2.3%) NCT05763875 · Phase 3 · registry result, not featured evidence covid-19 7.7% injection site pain 7.7% blood creatine phosphokinase increased 4.3% NCT04929249 · Phase 3 · registry result, not featured evidence covid-19 18.3% urinary tract infection 3.5% hypertension 3.2% NCT03814187 · Phase 3 · registry result, not featured evidence covid-19 11.8% diabetes mellitus inadequate control 7.5% hypertension 7% NCT03814187 · Phase 3 · registry result, not featured evidence covid-19 11.9% diabetes mellitus inadequate control 7.4% hypertension 7.4% NCT03814187 · Phase 3 · registry result, not featured evidence back pain 0.4% injection site rash 0.4% muscle spasms 0.4% NCT04807400 · Phase 3 · registry result, not featured evidence dizziness 0.4% rash 0.4% back pain 0% NCT04807400 · Phase 3 · registry result, not featured evidence · combination diarrhoea 5.4% (placebo 0%) pyrexia 5.4% (placebo 0%) respiratory tract infection viral 5.4% (placebo 10.5%) NCT03851705 · Phase 3 · registry result, not featured evidence corona virus infection 7.5% (placebo 0%) international normalised ratio increased 5.7% (placebo 0%) activated partial thromboplastin time prolonged 3.8% (placebo 0%) NCT03851705 · Phase 3 · registry result, not featured evidence 300 mg pyrexia 18.2% (placebo 12.3%) diabetes mellitus inadequate control 15.2% (placebo 15.8%) diabetes mellitus 12.1% (placebo 8.8%) NCT04666298 · Phase 2 · registry result, not featured evidence 200 mg diabetes mellitus 11.9% (placebo 8.8%) injection site reaction 11.9% (placebo 3.5%) pyrexia 11.9% (placebo 12.3%) NCT04666298 · Phase 2 · registry result, not featured evidence 100 mg diabetes mellitus 20% (placebo 8.8%) covid-19 14.5% (placebo 3.5%) pyrexia 14.5% (placebo 12.3%) NCT04666298 · Phase 2 · registry result, not featured evidence nasopharyngitis 19.4% (placebo 6.7%) hypertension 14.8% (placebo 2.2%) arthralgia 14.1% (placebo 11.1%) NCT03060577 · Phase 2 · registry result, not featured evidence hypertension 19.5% (placebo 2.2%) back pain 14.9% (placebo 1.1%) nasopharyngitis 14.9% (placebo 6.7%) NCT03060577 · Phase 2 · registry result, not featured evidence abdominal pain upper 25% acne 25% angina unstable 25% NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy 300 mg double dose nasopharyngitis 18% (placebo 12.9%) musculoskeletal pain 9.8% (placebo 6.5%) diarrhoea 8.2% (placebo 3.2%) NCT02597127 · Phase 2 · registry result, not featured evidence 300 mg single dose nasopharyngitis 14.8% (placebo 12.9%) cough 11.5% (placebo 4.8%) myalgia 9.8% (placebo 4.8%) NCT02597127 · Phase 2 · registry result, not featured evidence 500 mg single dose nasopharyngitis 13.8% (placebo 12.9%) influenza 7.7% (placebo 3.2%) upper respiratory tract infection 7.7% (placebo 3.2%) NCT02597127 · Phase 2 · registry result, not featured evidence 200 mg double dose diarrhoea 11.3% (placebo 3.2%) cough 9.7% (placebo 4.8%) arthralgia 8.1% (placebo 1.6%) NCT02597127 · Phase 2 · registry result, not featured evidence 200 mg single dose nasopharyngitis 13.3% (placebo 12.9%) arthralgia 6.7% (placebo 1.6%) back pain 6.7% (placebo 3.2%) NCT02597127 · Phase 2 · registry result, not featured evidence 100 mg double dose nasopharyngitis 13.1% (placebo 12.9%) myalgia 11.5% (placebo 4.8%) back pain 9.8% (placebo 3.2%) NCT02597127 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 40 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Inclisiran
show 76 more results
show 38 more results
show 38 more results
show 23 more results
show 34 more results
show 34 more results
show 6 more results
show 6 more results
show 6 more results
show 6 more results
show 27 more results
show 2 more results
+ 58 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: COR-1004's landscape · Inclisiran's landscape